Education
About Us
Working with TipRanks
Follow Us
Neurogene (NGNE)
NASDAQ:NGNE
NGNE Stock Chart & Stats
$16.89
-$0.86(-3.93%)
At close: 4:00 PM EST
$16.89
-$0.86(-3.93%)
Day’s Range― - ―
52-Week Range$6.88 - $37.27
Previous CloseN/A
Volume20.02K
Average Volume (3M)225.72K
Market Cap
$261.62M
Enterprise Value$209.48M
Total Cash (Recent Filing)$265.41M
Total Debt (Recent Filing)$11.27M
Price to Earnings (P/E)―
Beta3.19
Next Earnings
Mar 23, 2026EPS Estimate
-1.18Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.99
Shares Outstanding15,489,800
10 Day Avg. Volume272,921
30 Day Avg. Volume225,725
Financial Highlights & Ratios
PEG Ratio-0.10
Price to Book (P/B)1.29
Price to Sales (P/S)434.14
P/FCF Ratio-5.62
Enterprise Value/Market Cap0.80
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-13.65
Enterprise Value/Ebitda-2.49
Forecast
1Y Price Target
$60.00Price Target Upside255.24% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering4
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Clinical Efficacy And DurabilityPhase I/II data show deep, multi-domain developmental gains that continue to deepen over extended follow-up, supporting a higher probability of approval and clear clinical differentiation.
Commercial Access And ReimbursementExtensive payer engagement and commercial preparation indicate intracerebroventricular administration is unlikely to block reimbursement, supporting potential broad treatment access.
Regulatory DesignWritten FDA alignment on a clear responder-based composite endpoint and an endorsed responder definition reduces regulatory risk for the pivotal trial.
Bears Say
Execution RiskA tight competitive landscape makes successful execution on Biologics License Application mechanics and trial operations decisive, increasing the chance that operational setbacks could delay approval.
Perception And Narrative RiskExternal commentary and shifting market narratives risk widening the disconnect between clinical data and investor perception, potentially exerting downside pressure independent of scientific progress.
Valuation DisconnectThe share price has weakened despite a differentiated dataset, reflecting a market valuation gap that could persist until clearer clinical or regulatory milestones are delivered.
Neurogene News
NGNE FAQ
What was Neurogene’s price range in the past 12 months?
Neurogene lowest stock price was $6.88 and its highest was $37.27 in the past 12 months.
What is Neurogene’s market cap?
Neurogene’s market cap is $261.62M.
When is Neurogene’s upcoming earnings report date?
Neurogene’s upcoming earnings report date is Mar 23, 2026 which is in 36 days.
How were Neurogene’s earnings last quarter?
Neurogene released its earnings results on Nov 13, 2025. The company reported -$0.99 earnings per share for the quarter, beating the consensus estimate of -$1.249 by $0.259.
Is Neurogene overvalued?
According to Wall Street analysts Neurogene’s price is currently Undervalued.
Does Neurogene pay dividends?
Neurogene does not currently pay dividends.
What is Neurogene’s EPS estimate?
Neurogene’s EPS estimate is -1.18.
How many shares outstanding does Neurogene have?
Neurogene has 15,489,800 shares outstanding.
What happened to Neurogene’s price movement after its last earnings report?
Neurogene reported an EPS of -$0.99 in its last earnings report, beating expectations of -$1.249. Following the earnings report the stock price went down -14.043%.
Which hedge fund is a major shareholder of Neurogene?
Currently, no hedge funds are holding shares in NGNE
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Neurogene Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$60.00 (255.24% Upside)
$60.00 (255.24% Upside)
Crowd Wisdom
Neutral
Last 7 Days ▼ 0.9%
Last 30 Days ▲ 0.8%
Last 30 Days ▲ 0.8%
Technicals
SMA
Positive
20 days / 200 days
Momentum
-45.14%
12-Months-Change
Fundamentals
Return on Equity
-42.25%
Trailing 12-Months
Asset Growth
65.34%
Trailing 12-Months
Company Description
Neurogene
Neurogene Inc. develops life-changing genetic medicines for patients and their families affected by neurological diseases. Its product candidate includes NGN-401, an investigational AAV9 gene therapy for the treatment of Rett syndrome; and NGN-101 to treat neuronal ceroid lipofuscinosis subtype 5 batten disease. The company is headquartered in New York, New York.
NGNE Stock 12 Month Forecast
Average Price Target
$60.00
▲(255.24% Upside)
Technical Analysis
Silence Therapeutics
―
Atea Pharmaceuticals
―
Elicio Therapeutics
―
Vor Biopharma
―
Tenaya Therapeutics
―